Mechanisms of Radiosensitization by the Neurotensin Receptor Antagonist SR48692 in Prostate Cancer Models

Abstract

This project tests the hypothesis that blocking neurotensin receptor 1 (NTR1) with a specific antagonist, SR48692, could sensitize prostate cancer to ionizing radiation, thus improving outcomes of radiotherapy. We demonstrated that SR48692 selectively sensitizes prostate cancer cells but not normal prostate epithelial cells, most plausibly due to the differences in NTR1 expression. We also observed drug-dependent radiosensitization in orthotopic xenografts of human prostate cancer cells in mice. Importantly, the sensitization did not depend on AR expression, suggesting that anti-NTR1 treatment could be used to enhance radiotherapy of both androgen-dependent and independent tumors.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Apr 01, 2011
Accession Number
ADA547627

Entities

People

  • Jaroslaw Dziegielewski

Organizations

  • University of Virginia

Tags

DTIC Thesaurus Topics

  • Androgen Receptors
  • Apoptosis
  • Cell Line
  • Cell Physiological Processes
  • Cells
  • Central Nervous System
  • Chemistry
  • Department Of Defense
  • Epithelial Cells
  • Ionizing Radiation
  • Medical Personnel
  • Mrna
  • Neoplasms
  • Peptides
  • Prostate Cancer
  • Proteins
  • Radiation

Fields of Study

  • Biology
  • Medicine

Readers

  • Cardiovascular Physiology
  • Molecular Biology and Genetics
  • Women's Health and Cancer Risk Research: African American Women and Pregnancy Outcomes.